Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition
- In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in lean muscle mass and a reduction in fat mass
- Data provide first human proof-of-mechanism and support Atrogi’s planned Phase 2 trial expected to initiate in 2027
Stockholm, Sweden, October 1, 2026 – Atrogi AB, a clinical-stage biotech company pioneering novel GPCR pathway-signalling modulators to transform metabolic and muscle health, today announces positive data from a human trial for its lead candidate ATR-258, a first-in-class small molecule oral GRK2-biased β2-adrenergic modulator.
